EAM
RCKT icon

EFG Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

EFG Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110,961
Closed -$737K – 184
2025
Q1 		$737K Sell
110,961
-34,668
-24% -$343K 0.12% 176
2024
Q4 		$1.83M Sell
145,629
-98,791
-40% -$1.49M 0.25% 162
2024
Q3 		$4.52M Buy
244,420
+22,374
+10% +$458K 0.76% 24
2024
Q2 		$4.78M Buy
222,046
+71,044
+47% +$1.63M 0.83% 22
2024
Q1 		$4.06M Sell
151,002
-4,203
-3% -$119K 0.7% 39
2023
Q4 		$4.64M Buy
155,205
+4,137
+3% +$91.3K 0.88% 24
2023
Q3 		$3.09M Buy
151,068
+11,045
+8% +$201K 0.73% 47
2023
Q2 		$2.78M Buy
140,023
+1,968
+1% +$39.8K 0.6% 57
2023
Q1 		$2.37M Buy
138,055
+25,553
+23% +$500K 0.52% 63
2022
Q4 		$2.19M Buy
+112,502
New +$2.07M 0.49% 69

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

EFG Asset Management's RCKT Position: Q2 2025 in Review

EFG Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 110,961 shares — an estimated $737K sold.

EFG Asset Management first reported a position in RCKT in Q4 2022 and held it in 10 quarters. The position peaked at $4.78M in Q2 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • EFG Asset Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • EFG Asset Management sold 110,961 Rocket Pharmaceuticals shares in Q2 2025, an estimated $737K.
  • EFG Asset Management first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • EFG Asset Management's Rocket Pharmaceuticals position peaked at $4.78M in Q2 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on EFG Asset Management's 13F filing for Q2 2025, filed 6 Aug 2025.